Written by The weight loss treatment landscape is evolving at an unprecedented pace. While GLP-1 medications have revolutionised obesity care, the next wave of innovation addresses the remaining challenges—muscle preservation, tolerability, and convenience. Weight Loss Treatment in Riyadh For those exploring a Weight Loss Treatment in Riyadh, understanding these emerging options can help you anticipate what the future of care may hold.
The Pill Revolution: Oral GLP-1s Arrive
A Needle-Free Option for More Patients
The era of injectable-only GLP-1s is ending. Two oral GLP-1s are now FDA-approved: Novo Nordisk’s WEGOVY pill and Eli Lilly’s FOUNDAYO, marking a shift toward more accessible treatments . Clinical trials show these oral options deliver meaningful weight loss—FOUNDAYO achieved 12.4% weight loss over 72 weeks, with over 54% of participants losing ≥10% of their body weight . The convenience of daily tablets could significantly improve long-term adherence.
Elecoglipron: A New Oral Small Molecule
AstraZeneca’s elecoglipron represents a distinct approach. Unlike peptide-based medications that require cold storage and fasting, elecoglipron is a small molecule taken once daily without food restrictions . Phase 2 trials demonstrated 11.8% weight loss at 36 weeks at the highest dose, with improvements in blood pressure and cardiometabolic risk factors . The drug has now entered Phase 3 development .
Once-Monthly Dosing: Changing the Adherence Game
Berobenatide’s Monthly GLP-1
Pfizer’s berobenatide is a potential first-in-class once-monthly GLP-1 receptor agonist. Phase 2b trials demonstrated substantial weight loss, with the highest weekly dose achieving 15.9% weight loss at 32 weeks with no plateau. Notably, weight loss continued after patients transitioned from weekly to monthly dosing . If approved, monthly administration could dramatically improve treatment adherence and simplify management for patients.
Multi-Hormone Agonists: More Targets, More Benefit
Survodutide’s GLP-1/Glucagon Approach
Survodutide, a dual GLP-1/glucagon agonist, targets fullness and energy expenditure. Phase 3 data show 13.0% weight loss over 76 weeks, with benefits extending to liver health—up to 62% of patients achieved ≥30% reduction in liver fat . This suggests significant potential for treating both obesity and fatty liver disease.
Triple Agonists on the Horizon
Retatrutide, targeting GLP-1, GIP, and glucagon, is in development. Early trials have produced weight loss approaching what’s typically seen with bariatric surgery . These multi-hormone approaches aim to improve efficacy while maintaining acceptable tolerability.
Muscle Preservation: The Next Frontier
Protecting Lean Mass During Weight Loss
A key concern with existing therapies is muscle loss. At UC Berkeley, researchers have identified TOFA, a compound that helps cells burn more energy while preserving lean mass—without reducing food intake . In mice, TOFA combined with GLP-1 drugs produced additive improvements in weight loss and metabolic health . Human studies are needed, but this represents a promising direction for protecting muscle during weight loss.
ActR2 Pathway Inhibition
FBL-140, a once-monthly ActR2A/B antagonist, has shown potential for high-quality weight loss—reducing fat while preserving muscle . This approach addresses a growing concern in obesity management.
Amylin: Better Tolerability with Meaningful Effect
Petrelintide, an investigational amylin analog, produced meaningful weight loss (around 15%) with a remarkably favourable tolerability profile. In one study, side effects were equivalent to placebo . Roche is advancing both petrelintide and its GLP-1/GIP agonist enicepatide through late-stage development .
What This Means for Patients
The weight loss treatment landscape is expanding rapidly. A 2026 Clarivate report identified multiple emerging approaches—oral delivery, ultra-long-acting therapies, muscle-preserving mechanisms, and novel non-incretin pathways . These innovations aim to improve efficacy, tolerability, and accessibility.
For those considering a Weight Loss Treatment in Riyadh, the coming years will bring more options tailored to individual needs. Consulting a healthcare provider who stays informed about emerging therapies can help you make the best choice for your health.
For those seeking expert guidance and customised aesthetic care, you can book an appointment consultation at the Enfield Royal Clinic.
Frequently Asked Questions
Are oral GLP-1s as effective as injectable ones?
Clinical trials show oral GLP-1s achieve 12-14% weight loss over 12-18 months, slightly lower than some injectables but offering greater convenience .
What are the most promising new weight loss medications?
Survodutide (dual GLP-1/glucagon), retatrutide (triple agonist), and petrelintide (amylin analog) are generating strong clinical data .
Will new treatments preserve muscle during weight loss?
Yes, several emerging therapies—including ActR2 antagonists and metabolic modulators—are designed to protect lean mass while reducing fat .
When will once-monthly GLP-1 medications be available?
Berobenatide, a once-monthly GLP-1, is in Phase 3 trials. If approved, it could become the first monthly GLP-1 receptor agonist .
Are there non-incretin weight loss treatments in development?
Yes. Researchers are exploring therapies targeting muscle preservation, metabolic rate, and other pathways, aiming to address different aspects of obesity .